The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
Subscribe To Our Newsletter & Stay Updated
